Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Works Technologies ABXSAT:BIOWKS +0.59%68 PB Ratio is 6.15 as of Aug. 21, 2026, which is 9% above its 10-year median of 5.65. GuruFocus rates XSAT:BIOWKS with a GF Score™ of 68/100 and a GF Value™ of kr3.62 (Fairly Valued). The stock has 2 warning signs investors should review. Among 780 Medical Devices & Instruments companies, Bio-Works Technologies AB ranks worse than 84.36% on this metric.
Bio-Works Technologies AB stock PB Ratio (=5.79) is close to 1-year low of 5.47.
The historical rank and industry rank for Bio-Works Technologies AB's PB Ratio or its related term are showing as below:
XSAT:BIOWKS'
s PB Ratio Range Over the Past 10 Years
Min: 1.1 Med: 5.65 Max: 23.22
Current: 6.16
During the past 11 years, Bio-Works Technologies AB's highest PB Ratio was 23.22. The lowest was 1.10. And the median was 5.65.
XSAT:BIOWKS's PB Ratio is ranked worse than 84.36% of 780
companies
in the Medical Devices & Instruments industry
Industry Median: 2.145
vs XSAT:BIOWKS: 6.16
During the past 12 months, Bio-Works Technologies AB's average Book Value Per Share Growth Rate was 18.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -28.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.90% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Bio-Works Technologies AB was 40.00% per year. The lowest was -37.10% per year. And the median was -6.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bio-Works Technologies AB PB Ratio Related Terms
Bio-Works Technologies AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:BIOWKS vs ISRG, BDX, MDLN: PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bio-Works Technologies AB (XSAT:BIOWKS) has a PB Ratio of 6.15 as of Aug. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Works Technologies AB and its competitors. This is near median its historical median of 5.65. Over the past decade, Bio-Works Technologies AB's PB Ratio has ranged from 1.10 to 23.22. According to the industry distribution chart, Bio-Works Technologies AB ranks #658 out of 780 companies in the Medical Devices & Instruments industry, placing it in the top 84.4%.
Is Bio-Works Technologies AB's PB Ratio too high?
Bio-Works Technologies AB's current PB Ratio of 6.15 is near median its 10-year median of 5.65. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 23.22. The Medical Devices & Instruments industry median PB Ratio is 2.15. Bio-Works Technologies AB's value of 6.15 is 186.7% above this industry median. Based on the distribution chart, Bio-Works Technologies AB ranks #658 out of 780 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Works Technologies AB has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Works Technologies AB ranks #658 out of 780 companies for PB Ratio. This places Bio-Works Technologies AB in the lower half of its industry. The industry median PB Ratio is 2.15. Bio-Works Technologies AB's value of 6.15 is 186.7% above this benchmark. Historically, Bio-Works Technologies AB's own PB Ratio has ranged from 1.10 to 23.22 over the past decade. While the company's 10-year median is 5.65 vs. the industry median of 2.15, Bio-Works Technologies AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.15, based on 780 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Works Technologies AB's current PB Ratio of 6.15 is 186.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Works Technologies AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Works Technologies AB's current PB Ratio is 6.15, which is near median its own 10-year median of 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (XSAT:BIOWKS) is currently considered Fairly Valued. The stock's GF Value™ is kr3.62, compared to a current price of kr3.40 — trading 6.1% below its estimated fair value. The current PB Ratio is 6.15, which is near median its 10-year median of 5.65 and 186.7% above the Medical Devices & Instruments industry median of 2.15. Bio-Works Technologies AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bio-Works Technologies AB (XSAT:BIOWKS), the current PB Ratio is 6.15 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (XSAT:BIOWKS) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of kr3.40 is trading 6.1% below its estimated GF Value™ of kr3.62.
GuruFocus considers Bio-Works Technologies AB to be Fairly Valued.
Key valuation signals for XSAT:BIOWKS:
PB Ratio: 6.15 (near median its 10-year median of 5.65)
GF Value™: kr3.62 vs. price of kr3.40 (6.1% below fair value)
Industry Position: 186.7% above the Medical Devices & Instruments median (#658 of 780)
No single metric tells the full story. See the XSAT:BIOWKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
68GF Score
Get the complete analysis for XSAT:BIOWKS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:BIOWKS has been successfully added to your 
